Cancer Immunotherapy News and Research

RSS
U.S., Canada research institutions to participate in NCI's Cancer Immunotherapy Trials Network

U.S., Canada research institutions to participate in NCI's Cancer Immunotherapy Trials Network

Roswell Park Cancer Institute selected to be part of Cancer Immunotherapy Trials Network

Roswell Park Cancer Institute selected to be part of Cancer Immunotherapy Trials Network

FDA approves ipilimumab for metastatic melanoma treatment

FDA approves ipilimumab for metastatic melanoma treatment

BMY receives FDA approval for YERVOY to treat metastatic melanoma

BMY receives FDA approval for YERVOY to treat metastatic melanoma

Oxford Biomedica’s TroVax(R) TRIST Phase III study results to be published in Cancer Immunology, Immunotherapy

Oxford Biomedica’s TroVax(R) TRIST Phase III study results to be published in Cancer Immunology, Immunotherapy

CIC to host Scientific Colloquium on tumor immunotherapy in National Harbor, MD

CIC to host Scientific Colloquium on tumor immunotherapy in National Harbor, MD

Patrys succeeds in obtaining commercial yields for its anti-cancer antibody therapeutic

Patrys succeeds in obtaining commercial yields for its anti-cancer antibody therapeutic

EMA grants Prima BioMed Scientific Advice for CVac ovarian cancer vaccine Phase III trial

EMA grants Prima BioMed Scientific Advice for CVac ovarian cancer vaccine Phase III trial

Advaxis added to Mentor Capital Cancer Immunotherapy Index

Advaxis added to Mentor Capital Cancer Immunotherapy Index

Inovio publishes scientific paper detailing SynCon DNA vaccine preclinical study for prostate cancer

Inovio publishes scientific paper detailing SynCon DNA vaccine preclinical study for prostate cancer

Cohort Review Committee evaluates SCIB1 dose escalation, safety in Phase 1 trial

Cohort Review Committee evaluates SCIB1 dose escalation, safety in Phase 1 trial

Agenus enters research agreement with Memorial Sloan-Kettering Cancer Center

Agenus enters research agreement with Memorial Sloan-Kettering Cancer Center

Additional data from HyperAcute Pancreas cancer immunotherapy Phase 2 trial to be presented at ASCO 2011

Additional data from HyperAcute Pancreas cancer immunotherapy Phase 2 trial to be presented at ASCO 2011

CRI introduces new model of philanthropic investment to improve cancer patient care

CRI introduces new model of philanthropic investment to improve cancer patient care

Tolerx commences TRX518 Phase 1 trial in malignant melanoma

Tolerx commences TRX518 Phase 1 trial in malignant melanoma

Tolerx enters collaborative research agreement with Cancer Research Institute

Tolerx enters collaborative research agreement with Cancer Research Institute

NCI awards $11.5 million to Fred Hutchinson Center for breast cancer research

NCI awards $11.5 million to Fred Hutchinson Center for breast cancer research

Hemispherx Biopharma awarded grant for Ampligen, Alferon development programs

Hemispherx Biopharma awarded grant for Ampligen, Alferon development programs

New immunoSEQ bioinformatics software platform helps monitor adaptive immune system

New immunoSEQ bioinformatics software platform helps monitor adaptive immune system

MannKind begins MKC1106-MT Phase 2 trial for advanced melanoma

MannKind begins MKC1106-MT Phase 2 trial for advanced melanoma

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.